Law360, New York (May 29, 2012, 2:21 PM ET) -- Watson Pharmaceuticals Inc. and Endo Pharmaceuticals Inc. have settled all of their outstanding patent litigation related to Watson's generic version of the brand-name lidocaine patch Lidoderm, the drugmakers said Tuesday.
The settlement agreement allows Watson to launch its 5 percent lidocaine topical patch product on Sept. 15, 2013, if the generic is approved by the U.S. Food and Drug Administration.
"We are pleased to have reached an agreement that protects Endo's intellectual property interests and eliminates the uncertainty of a court decision," Endo President and CEO...
Watson, Endo Settle Generic Lidoderm Patent Suit
To view the full article, take a free trial now.
